Outeda-García, MichelleGarcía-Pose, AndreaGuijarro-Sánchez, PaulaRodríguez-Coello, AriannaBáez-Barroso, Gabriela AlejandraMaceiras, RominaAlonso-García, IsaacArca-Suárez, JorgeVázquez-Ucha, Juan CarlosBou, GermánBeceiro Casas, Alejandro2025-09-032025-09-032025-05-20Outeda-García M, Garcia-Pose A, Guijarro-Sánchez P, Rodríguez-Coello A, Báez-Barroso GA, Maceiras R, Alonso-García I, Arca-Suárez J, Vázquez-Ucha JC, Bou G, Beceiro A; Spanish National Acinetobacter spp. 2020 Study Group. The novel polymyxin analogue SPR206 exhibits higher activity than colistin against both colistin-susceptible and colistin-resistant strains of Acinetobacter baumannii. Antimicrob Agents Chemother. 2025 Jul 2;69(7):e0194024.0066-4804https://hdl.handle.net/2183/45707[Abstract] Colistin resistance is increasing globally and complicates treatments of A. baumannii infections. The next-generation polymyxin SPR206 shows potent activity against multidrug-resistant Gram-negative pathogens with low toxicity. SPR206 exhibited higher activity against colistin-susceptible and colistin-resistant strains (MIC50/MIC90 = 0.12/0.25 mg/L), and resistance was only detected in 1/118 strains (MIC ≥4 mg/L). Mutations in pmrCAB, linked to colistin resistance, do not seem to confer resistance to the novel polymyxin, which retains a high level of activity.engAttribution 4.0 Internationalhttp://creativecommons.org/licenses/by/4.0/Acinetobacter baumanniiSPR206Antimicrobial resistanceColistinjournal articleopen access10.1128/aac.01940-24